MPA (Medroxyprogesterone acetate)

製品コードS2567 バッチS256702

化学情報

	Synonyms	NSC-26386, Medroxyprogesterone 17-acetate, Farlutin	Storage (From the date of receipt)	3 years -20°C powder 1 years -80°C in solvent
	化学式	C₂₄H₃₄O₄
	分子量	386.52	CAS No.	71-58-9
Solubility (25°C)*	体外	DMSO	12 mg/mL (31.04 mM)
		Ethanol	12 mg/mL warmed with 50ºC water bath (31.04 mM)
		Water	Insoluble
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	MPA (Medroxyprogesterone acetate) is a synthetic progestin and act as a potent progesterone receptor agonist, used to treat abnormal menstruation or irregular vaginal bleeding.
in vitro	Medroxyprogesterone acetate (MPA) inhibits the enzyme 3-hydroxyste-roid dehydrogenase, involved in the reversible conversion between 5alpha-dihydroprogesterone (DHP) and 3alpha, 5alpha-tetrahydroprogesterone (THP), and therefore may affect the local actions of DHP and THP in the brain. ^[1] Medroxyprogesterone acetate (MPA) reduces secretion of IL-6 and PTHrP from human breast cancer cells. MPA dose-dependently decreases the secretion and mRNA expression of IL-6 and PTHrP in the KTC-2 cells. ^[2] Medroxyprogesterone acetate (MPA) and dexamethasone dose dependently increases alpha-ENaC promoter-driven luciferase activity in M-1 cells, which is not inhibited by Org31710, indicating that Medroxyprogesterone acetate regulates alpha-ENaC in a PR-independent manner. Medroxyprogesterone acetate and dexamethasone, but not progesterone, dose dependently increases alpha-ENaC and sgk1 mRNA in M-1 and in Madin-Darby canine kidney-C7 cells, both collecting duct cell lines. ^[3] Medroxyprogesterone acetate (MPA) (0.1 nM) significantly enhances the in vitro production of specific immunoglobulin G (IgG) antibodies, an effect that appears to involve the interaction of the progestin with PRG receptors^[4]
in vivo	Medroxyprogesterone acetate (MPA) impairs delayed memory retention on the water radial-arm maze (WRAM), and exacerbates overnight forgetting on the Morris maze (MM) in aged ovariectomized (OVX) rats. Medroxyprogesterone acetate (MPA) significantly and progesterone marginally decreases GAD levels in the hippocampus, and both MPA and progesterone significantly increases GAD levels in the entorhinal cortex. ^[5]

製品説明

MPA (Medroxyprogesterone acetate) is a synthetic progestin and act as a potent progesterone receptor agonist, used to treat abnormal menstruation or irregular vaginal bleeding.

in vitro

Medroxyprogesterone acetate (MPA) inhibits the enzyme 3-hydroxyste-roid dehydrogenase, involved in the reversible conversion between 5alpha-dihydroprogesterone (DHP) and 3alpha, 5alpha-tetrahydroprogesterone (THP), and therefore may affect the local actions of DHP and THP in the brain. ^[1]

Medroxyprogesterone acetate (MPA) reduces secretion of IL-6 and PTHrP from human breast cancer cells. MPA dose-dependently decreases the secretion and mRNA expression of IL-6 and PTHrP in the KTC-2 cells. ^[2]

Medroxyprogesterone acetate (MPA) and dexamethasone dose dependently increases alpha-ENaC promoter-driven luciferase activity in M-1 cells, which is not inhibited by Org31710, indicating that Medroxyprogesterone acetate regulates alpha-ENaC in a PR-independent manner. Medroxyprogesterone acetate and dexamethasone, but not progesterone, dose dependently increases alpha-ENaC and sgk1 mRNA in M-1 and in Madin-Darby canine kidney-C7 cells, both collecting duct cell lines. ^[3]

Medroxyprogesterone acetate (MPA) (0.1 nM) significantly enhances the in vitro production of specific immunoglobulin G (IgG) antibodies, an effect that appears to involve the interaction of the progestin with PRG receptors^[4]

in vivo

Medroxyprogesterone acetate (MPA) impairs delayed memory retention on the water radial-arm maze (WRAM), and exacerbates overnight forgetting on the Morris maze (MM) in aged ovariectomized (OVX) rats. Medroxyprogesterone acetate (MPA) significantly and progesterone marginally decreases GAD levels in the hippocampus, and both MPA and progesterone significantly increases GAD levels in the entorhinal cortex. ^[5]

プロトコル(参考用のみ)

細胞アッセイ	細胞株	ISK cells
	濃度	29.3 µM
	反応時間	48 h
	実験の流れ	Cells were treated with various concentrations of drug for 48 h.
動物実験	動物モデル	Wistar albino female rats
	投薬量	1, 2, 4, or 8 mg/kg
	投与方法	i.p.

参考

+ 展开

カスタマーフィードバック

: Data from [Data independently produced by , , Molecular Pain, 2015, 11:46.]

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

The role of non-genomic actions of progesterone and its membrane receptor agonist in ovarian cancer cell death [ Cancer Rep (Hoboken), 2024, 7(1):e1934]	PubMed: 38013666
Genome-wide CRISPR screening reveals ADCK3 as a key regulator in sensitizing endometrial carcinoma cells to MPA therapy [ Br J Cancer, 2023, 129(4):601-611]	PubMed: 37402867
Genome-wide CRISPR screening reveals ADCK3 as a key regulator in sensitizing endometrial carcinoma cells to MPA therapy [ Br J Cancer, 2023, 129(4):601-611]	PubMed: 37402867
Elevated high-mannose N-glycans hamper endometrial decidualization [ iScience, 2023, 10.1016/j.isci.2023.108170]	PubMed: 37915610
RNA-seq and ATAC-seq analysis of CD163+ macrophage-induced progestin-insensitive endometrial cancer cells [ Cancer Med, 2023, 12(5):5964-5978]	PubMed: 36373483
ABX-1431 inhibits the development of endometrial adenocarcinoma and reverses progesterone resistance by targeting MGLL [ Cell Death Dis, 2022, 13(12):1067]	PubMed: 36550099
Chlorpromazine Sensitizes Progestin-Resistant Endometrial Cancer Cells to MPA by Upregulating PRB [ Front Oncol, 2021, 11:665832]	PubMed: 33937078
Characteristics of Circular RNA Expression in Ishikawa Human Endometrial Carcinoma Cells with Progesterone Treatment [ Research Square, 2020, 10.21203/rs.3.rs-30247/v1]	PubMed: None
poFUT1 promotes endometrial decidualization by enhancing the O-fucosylation of Notch1 [ EBioMedicine, 2019, 44:563-573]	PubMed: 31201143
poFUT1 promotes uterine angiogenesis and vascular remodeling via enhancing the O-fucosylation on uPA [ Cell Death Dis, 2019, 10(10):775]	PubMed: 31601791

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。